Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma.

8524 Background: Anti-CTLA4 antibodies and HDI have significant immunomodulatory and antitumor activity in advanced melanoma. We hypothesized that the combination might abrogate immunologic toleran...